In 1996, the chemokine receptor CCR5 was shown to be involved in the process by which the human immunodeficiency virus (HIV) gains entry into CD4 + lymphocytes. 1 Shortly after this discovery it was found that inheritance of a naturally occurring 32 base pair (bp) deletion in the receptor's gene (CMKBR5) significantly reduces the risk of infection in those exposed to HIV, 2 the deletion bearing allele (∆ccr5) coding for a non-functioning protein. 2 These observations raised the possibility that chemokine receptor polymorphisms, such as ∆ccr5, might be important determinants in the development of other retroviral diseases. Although the environmental factor involved in the pathogenesis of multiple sclerosis is uncertain, a novel retrovirus is one candidate. 3 With this in mind, Bennetts et al 4 compared the frequency of the ∆ccr5 allele in Australian patients with multiple sclerosis and unrelated controls, but found no evidence for a protective effect. More recently, Libert et al 5 studied the ∆ccr5 allele in a variety of healthy European populations (not including the UK) and found a striking north-south gradient in allele frequency. In addition, these investigators identified strong linkage disequilibrium (LD) between ∆ccr5 and flanking microsatellite markers suggesting a founder effect with most, if not all, contemporary ∆ccr5 alleles originating from a single ancestral mutation event. 5 In order to establish the role, if any, of ∆ccr5 in patients with multiple sclerosis from the United Kingdom we typed 185 simplex families (both parents and a single affected offspring). The ∆ccr5 allele frequency was 15.4% (57/370) in the 185 affected offspring, with genotype frequencies corresponding to those expected at Hardy Weinberg equilibrium. Transmission disequilibrium testing, 6, 7 performed using the sibtdt program from the ASPEX package version 1.12, revealed no significant evidence for distorted transmission, with 48 ∆ccr5 alleles transmitted and 34 not transmitted (indicating a transmission rate in the 95% confidence interval 47.6%-69.4%). It should be noted, of course, that the modest sample size used in our study means that a small effect from ∆ccr5 cannot be excluded.
The flanking dinucleotide microsatellites used by Libert et al (D3S4579 and D3S4580) were also typed in these 185 families; phase of the alleles in each parent was inferred from those transmitted and thereby the frequency of each marker allele in both the ∆ccr5 bearing chromosomes (n = 100) and the wild type chromosomes (n = 640) was calculated (coincidentally the D3S4580 marker was found to have a low frequency null allele, of about 7%). Highly significant linkage disequilibrium was found between ∆ccr5 and the 138 bp allele of D3S4579, and between ∆ccr5 and the 144 bp allele of D3S4580 (see Table) . These were confirmed as the same marker alleles found by Libert et al indicating that the UK ∆ccr5 alleles arose from the same common founder.
Although we have not found any evidence that ∆ccr5 is involved in determining susceptibility to multiple sclerosis, we confirm the findings of Libert et al. The existence of founder effects in large outbred populations (such as the Europeans) is a significant result in terms of polygenic disease. These data add to the growing evidence supporting the belief that LD frequently occurs in the region of disease genes. In monogenic diseases such as cystic fibrosis 8 the existence The region of the 32 bp deletion in the CCR5 gene was amplified using the primers TAG GTA CCT GGC TGT CGT CC and TTC CCG AGT AGC AGA TGA CC, the D3S4579 marker with primers AAG AGA TTG GTT CCA GGC ATG and CCG GAC CTT GCA TTA CAG GAC, and the D3S4580 marker with primers CCT TCT GGA GCA GCA CTT CCA and GTA AAT CTC CTA ACA ACA TGC. In each case the forward primer was fluorescently labelled and the genotyping was performed using the Applied Biosystems GENESCAN/GENOTYPER system. of LD is well established, whilst in polygenic disease similar evidence is now beginning to emerge.
